Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT.
We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.
Yoon
So Young
SY
Department of Hematooncology, Konkuk University Medical Center, Seoul, Korea. greenteamd@gmail.com
Kim
Sung-Yong
SY
Cho
Yo-Han
YH
Chung
Hyun Woo
HW
So
Young
Y
Lee
Hong M
HM
Eur J Nucl Med Mol Imaging. 2005 Feb;32(2):153-62
15690223
J Clin Oncol. 2007 May 1;25(13):1760-4
17470866
J Clin Oncol. 2006 Sep 10;24(26):4293-300
16908937
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Nucl Med. 2004 Mar;45(3):357-65
15001674
J Clin Oncol. 2006 Dec 10;24(35):5601-8
17158546
J Clin Oncol. 2007 May 1;25(13):1753-9
17470865
Eur J Cancer. 2003 Sep;39(14):2012-20
12957455